Skip to main content
Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors
Posters

Evaluation of a new co-cultured Microbiome Ecosystem Therapy candidate (MaaT03X) for clinical testing as adjuvant/neoadjuvant to immune checkpoint inhibitors in solid tumors

Date : 01/11/2023

MaaT Pharma dans les médias MaaT Pharma in the News Devenez membre du club Become a member of the club